Business

Know the Business

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Elixirr is a senior-led "challenger" consultancy that bills experienced Partners at premium rates and grows by stretching them, hiring more, and bolting on US/Nordic specialty firms. The 30% adjusted EBITDA margin is the giveaway — it is roughly double Accenture's and triple ICF's, and exists because the firm refuses the traditional pyramid that delivers analysts cheap and bills them expensive. The market is most likely overestimating how much of the FY25 34% revenue growth is durable — only 15% was organic — and underestimating how much equity dilution and contingent consideration is quietly funding the headline.

1. How This Business Actually Works

The product is one experienced Partner, sold by the day, on a fixed-outcome contract — supported by a small team of consultants, data engineers, and increasingly, AI tooling. There is no army of new graduates being marked up 5x; that is the entire model in one sentence.

The economic engine has three throttles. First, revenue per Partner — a Partner sold full-time at premium rates generates $5.9M a year, double the $4.1M at IPO, and this has compounded faster than headcount. Second, the Partner count — 34 client-facing Partners (up from 27 in FY24), grown by promoting Principals (3 in FY25), poaching laterals (2 in FY25), and by acquiring boutique firms with embedded senior teams (6 came with TRC). Third, cross-sell into the installed base — gold clients (those generating over $1.3M) rose from 27 to 34, and cross-capability revenue hit $50M, or 25% of the group, up from 17% the year before.

Both levers have moved every year since IPO. That is rare in services — most consultancies grow either by adding bodies (margin-dilutive) or by raising rates (capacity-capped). Elixirr has done both at once because the equity-participation model — 84% of consultants enrolled — recruits and retains people willing to take ownership over compensation, and AI tooling (45 internal agents, proposals built in 10% of prior time) absorbs the work the new graduates would have done.

The cost of the engine is hidden in two places investors should track. Stock-based compensation ran $6.3M in FY25 — 3.2% of revenue, up from 2.3% in FY21. That is the price of the equity model and it grows roughly linearly with headcount. Contingent consideration sits at $56.8M on the balance sheet — earnouts owed to acquired-firm sellers — versus $13.1M a year ago. Each acquisition is partly self-financing (sellers earn out only if their unit performs), but the cumulative liability has more than quadrupled.

2. The Playing Field

Elixirr is a fly in a room of elephants — its margin is the highest in the peer set, its scale the smallest, and the gap on both axes is enormous.

Revenue and market cap shown in $M for cross-currency comparability. Elixirr reports in GBP; figures converted at FY25 year-end FX (1.3466).

Three things stand out. ELIX is the only peer in the upper-right quadrant — high growth and high margin. The big peers (ACN, BAH) earn lower margins because they leverage juniors and absorb a far larger overhead structure; ELIX skips both. The mid-size US specialty firms (FCN, HURN, ICFI) operate at margins broadly comparable to ACN, which suggests it is not size that compresses margin — it is delivery model.

The gap on multiples is narrower than the gap on operations. Accenture is at ~12.5x EV/EBITDA on its FY25 close — and has de-rated meaningfully since (the stock has lost roughly 40% of its value over the past year on AI-substitution fears). ELIX at 11.5x is broadly in line with the big-cap peer despite triple-the-growth and double-the-margin. The market is essentially saying: "we do not believe the 30% margin and 34% growth are fully sustainable through-cycle." That is the bet to underwrite.

3. Is This Business Cyclical?

Consulting is a discretionary spend item — when corporate budgets tighten, transformation projects are the first to be shelved. So yes, the industry is cyclical, but Elixirr's reported numbers do not show it because the company has been in capture phase, growing through whatever cycle the market has thrown at it.

Adjusted EBITDA margin held a 24–30% band across the same period: 24% in FY20, 27% in FY22, 28% in FY24, 29.6% in FY25. The statutory operating margin reads lower (19.9% in FY25) because acquisition-related intangible amortisation now runs ~$9.7M a year — useful for cash flow analysis, misleading if compared to peers who do not amortise.

The cycle hits four places in this business. Demand: large transformation programmes get postponed when CFOs hold the purse strings — the first signal is end-of-programme attrition without replacement ($19.3M of attrition in FY25, fully absorbed by $42M of expansion). Pricing: rate cards hold up better than utilisation, so margins fall before they crater — Elixirr's adjusted EBITDA margin has held a 28–30% band through three different macro environments (post-COVID 2021, rate-shock 2023, AI-disruption 2024–25). Utilisation: the dangerous metric, not disclosed publicly — when Partners cannot fill their book, the senior-led model becomes a fixed-cost trap. Working capital: clients stretch payables in a slowdown, and FY25 already showed the early sign — receivables rose 46% as revenue rose 34%, dragging FCF growth (+11%) well below EBITDA growth (+42%).

The honest assessment: ELIX has never been tested by a real consulting recession. It IPO'd in July 2020 into a post-COVID rebound, expanded through the rate cycle on cross-sell and acquisition tailwinds, and is now riding the AI demand wave. The first true through-cycle test will reveal whether the senior-led model is anti-fragile (Partners absorb downside via lower variable comp) or vulnerable (Partners walk if equity cannot vest).

4. The Metrics That Actually Matter

Forget P/E and forget revenue growth in isolation. Five operating metrics tell you whether the engine is running.

Cross-sell at 25% is the most underrated number. It says the acquisitions are knitting together — TRC clients are buying Elixirr capability, Hypothesis is selling research into Elixirr accounts. If cross-sell stalls or reverses, the firm is just buying revenue at 6–8x EBITDA and then re-selling it at the same multiple in its own stock.

Free cash conversion at 70% is the early warning sign nobody talks about. Operating cash flow grew 12% on EBITDA growth of 42% — most of the gap is one big working-capital build, but if it persists into FY26 it implies either client stretch (cyclical) or aggressive revenue recognition (idiosyncratic). Either is bad.

5. What Is This Business Worth?

Value is mostly determined by earnings power × reinvestment runway, not by assets, segments, or hidden stakes. Tangible book value is negative $74M (intangibles are 79% of assets), so book is meaningless. There is no listed subsidiary, no holding-company discount to unwind, no separable business worth carving out. This is one engine, and the question is what flow rate it can sustain.

ELIX trades at roughly 22x trailing P/E and 11.5x EV/EBITDA on FY25 numbers — broadly in line with Accenture (21x P/E, 12.5x EV/EBITDA) and well below Huron (30x P/E). The right framing is not "is the multiple cheap or expensive" but "what part of the next three years' growth is in the price." If you believe the firm can sustain 12%+ organic growth and 28%+ EBITDA margin through a real consulting recession, the multiple looks defensive. If you think margins compress to peer levels in any meaningful slowdown, the multiple looks rich because earnings would re-rate in both directions.

A SOTP lens is not appropriate here. There are no separable parts disclosed — the acquired entities (TRC, Kvadrant, Hypothesis, Insigniam, iOLAP, Coast Digital) are operationally integrated into the Group, share clients, and cross-sell. Disaggregating them is artificial.

6. What I'd Tell a Young Analyst

Watch four things, ignore everything else.

Revenue per Partner. It has gone from $4.1M to $5.9M in five years on the back of pricing, mix, and AI-augmented productivity. If it stops compounding at 5%+, the model has hit a ceiling and you are now paying a growth multiple for a flat-productivity business. This is the single most important leading indicator.

Organic vs total growth. FY25's headline 34% is misleading — half of it is the wrap-around of Hypothesis (FY24 deal) and the September TRC consolidation. Strip those out, organic was 15.3%. Track this number quarterly. The day organic falls below 10% while the firm is still buying companies, you have a roll-up problem.

Contingent consideration as % of equity. $57M sits on the balance sheet against $192M of equity — almost 30%. Each earn-out paid is a real cash outflow that does not show up in EBITDA. Watch the cash payments line in financing flows; the headline FCF understates the full reinvestment cost.

The AI claim. "AI revenue grew 260%" sounds compelling but it is from a tiny base. The honest test is whether AI work shows up as margin expansion (Elixirr captures the productivity gain) or margin compression (clients pay less for AI-assisted work). FY25 margin expanded — give that one more year before declaring victory.

Two things the market may be missing in either direction. The bull case nobody underwrites: Elixirr is the rare consultancy without a junior pyramid to defend, so AI substitution is asymmetric upside, not downside. The bear case nobody flags: when the consulting cycle finally turns, Partners with vested equity options and no client demand have an outside option (start their own boutique, or take their book to McKinsey). The equity model that recruits in good times can disperse the firm in bad ones.

The thesis-changers are simple: organic growth dropping below 10% while M&A continues; EBITDA margin breaking 25% on the downside; revenue per Partner flatlining for two consecutive years; or contingent consideration getting settled at 100% without proportional revenue lift. Any one of those would force a re-underwrite.